Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 8
Submit an article Journal homepage
280
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Sarah Goldman-MazurDepartment of Hematology, Jagiellonian University Medical College, Cracow, Poland; Correspondence[email protected]
,
Artur JurczyszynDepartment of Hematology, Jagiellonian University Medical College, Cracow, Poland;
,
Jorge J. CastilloDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; ORCID Iconhttp://orcid.org/0000-0001-9490-7532
ORCID Icon,
Anna Waszczuk-GajdaDepartment of Hematology, Oncology and Internal Diseases, Warsaw Medical University, Warsaw, Poland; ORCID Iconhttp://orcid.org/0000-0001-5626-1750
ORCID Icon,
Norbert GrząśkoDepartment of Experimental Hematology, Medical University of Lublin, Lublin, Poland; ;Department of Hematology, St. John’s Cancer Center, Lublin, Poland;
,
Jakub Radocha4th Department of Internal Medicine – Hematology, University Hospital, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic;
,
Max BittrichDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany;
,
Klaus Martin KortümDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany; ORCID Iconhttp://orcid.org/0000-0002-7011-0286
ORCID Icon,
Alessandro GozzettiDivision of Hematology, Department of Medical Science, Surgery and Neuroscience, University of Siena, Siena, Italy;
,
Lidia Usnarska-ZubkiewiczDepartment of Hematology, Wroclaw Medical University, Wroclaw, Poland;
,
Julio D. VallsComplejo Asistencial de Avila, Avila, Spain;
,
David S. JayabalanWeill Cornell Medical College, New York, NY, USA;
,
Ruben NiesvizkyWeill Cornell Medical College, New York, NY, USA;
,
Julia KelmanWeill Cornell Medical College, New York, NY, USA;
,
Daniel CoriuDepartment of Hematology, Fundeni Clinical Institute, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania; ORCID Iconhttp://orcid.org/0000-0002-7251-6079
ORCID Icon,
Laura RosiñolDepartments of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain; ORCID Iconhttp://orcid.org/0000-0001-9531-961X
ORCID Icon,
Łukasz SzukalskiDepartment of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland;
,
Veronica González-CalleHospital Universitario de Salamanca/Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain;
,
María-Victoria MateosHospital Universitario de Salamanca/Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain; ORCID Iconhttp://orcid.org/0000-0003-2390-1218
ORCID Icon,
Krzysztof JamroziakInstitute of Hematology and Transfusion Medicine, Warsaw, Poland;
,
Iwona HusDepartment of Experimental Hematology, Medical University of Lublin, Lublin, Poland; ;Department of Hematology, St. John’s Cancer Center, Lublin, Poland; ;Institute of Hematology and Transfusion Medicine, Warsaw, Poland;
,
Irit AviviTel Aviv Sourasky Medical Center, Tel Aviv, Israel and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;
,
Yael CohenTel Aviv Sourasky Medical Center, Tel Aviv, Israel and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ORCID Iconhttp://orcid.org/0000-0002-9061-7287
ORCID Icon,
Piotr MazurInstitute of Cardiology, Jagiellonian University Medical College, Cracow, Poland; ORCID Iconhttp://orcid.org/0000-0003-4077-1232
ORCID Icon,
Anna SuskaDepartment of Hematology, Jagiellonian University Medical College, Cracow, Poland;
,
Aimee ChappellDepartment of Hematology/Oncology, Medstar Georgetown University Hospital, Washington, NW, USA;
,
Deepu MadduriIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA;
,
Saurabh ChhabraDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA;
,
Ariel KlemanDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA;
,
Parameswaran HariDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA;
,
Michel DelforgeDepartment of Hematology, UZ Leuven, Leuven, Belgium;
,
Paweł RobakDepartment of Experimental Hematology, Medical University of Lodz, Lodz, Poland;
,
Massimo GentileHematology Unit, AO Cosenza, Cosenza, Italy;
,
Izabela KozłowskaDepartment of Hematology, SPZOZ ZSM, Chorzow, Poland;
,
Stuart L. GoldbergJohn Theurer Cancer Center, Hackensack UMC, Hackensack, NJ, USA; ;Cota Inc, Boston, MA, USA;
,
Jacek CzepielDepartment of Infectious and Tropical Diseases, Jagiellonian University Medical College, Cracow, Poland;
,
Monika Długosz-DaneckaMaria Sklodowska-Curie National Institute of Oncology, Cracow, Poland; ORCID Iconhttp://orcid.org/0000-0002-8927-4125
ORCID Icon,
Rebecca SilbermannDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA;
,
Adam J. OlszewskiDepartment of Medicine, Warren Alpert Medical School, Brown University, Providence, RI, USA; ORCID Iconhttp://orcid.org/0000-0002-6472-6658
ORCID Icon,
Peter BarthDepartment of Medicine, Warren Alpert Medical School, Brown University, Providence, RI, USA;
,
Gabor MikalaDepartment of Hematology and Stem Cell Transplantation, South-Pest Central Hospital, National Institute of Hematology and Infectology, Budapest, Hungary;
,
Chor S. ChimDepartment of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong KongORCID Iconhttp://orcid.org/0000-0003-2427-915X
ORCID Icon &
David H. VesoleJohn Theurer Cancer Center, Hackensack UMC, Hackensack, NJ, USA;
show all
Pages 1885-1893 | Received 29 Jan 2020, Accepted 24 Mar 2020, Published online: 19 Apr 2020

References

  • Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385:2197–2208.
  • Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111:4039–4047.
  • Hanbali A, Hassanein M, Rasheed W, et al. The evolution of prognostic factors in multiple myeloma. Adv Hematol. 2017;2017:4812637.
  • Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–2869.
  • Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204:3–12.
  • Manier S, Salem K, Glavey SV, et al. Genomic aberrations in multiple myeloma. Cancer Treat Res. 2016;169:23–34.
  • Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360–376.
  • Greipp PRS, Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420.
  • Durie BG, Harousseau JL, Miguel JS, et al.; on behalf of the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473.
  • Ross FM, Chiecchio L, Dagrada G, et al.; on behalf of the UK Myeloma Forum. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica. 2010 ;95:1221–1225.
  • Boyd KD, Ross FM, Chiecchio L, et al.; on behalf of the NCRI Haematology Oncology Studies Group. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26:349–355.
  • Shah V, Sherborne AL, Walker BA, et al.; on behalf of the NCRI Haemato-oncology CSG. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32:102–110.
  • Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569–4575.
  • Avet-Loiseau H, Malard F, Campion L, et al.; for the Intergroupe Francophone du Myélome. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011;117:2009–2011.
  • Mai EK, Benner A, Bertsch U, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016;173:731–741.
  • Cavo M. Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02/H095 study. Blood. 2017;130:401.
  • Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116:e56–e65.
  • Narita T, Inagaki A, Kobayashi T, et al. t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer J. 2015;5:e285–e285.
  • Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008;140:625–634.
  • Qiang YW, Ye S, Chen Y, et al. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood. 2016;128:2919–2930.
  • Ross FM, Avet-Loiseau H, Ameye G, et al.; on behalf of the European Myeloma Network. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97:1272–1277.
  • Rack KA, van den Berg E, Haferlach C, et al. European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. Leukemia. 2019;33:1851–1867.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.